A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy
In: Lung Cancer ; volume 177, page 44-50 ; ISSN 0169-5002, 2023
academicJournal
Zugriff:
Titel: |
A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy
|
---|---|
Autor/in / Beteiligte Person: | Takeda, Masayuki ; Shimokawa, Mototsugu ; Nakamura, Atsushi ; Nosaki, Kaname ; Watanabe, Yasutaka ; Kato, Terufumi ; Hayakawa, Daisuke ; Tanaka, Hiroshi ; Takahashi, Toshiaki ; Oki, Masahide ; Tachihara, Motoko ; Fujimoto, Daichi ; Hayashi, Hidetoshi ; Yamaguchi, Kakuhiro ; Yamamoto, Shoichiro ; Iwama, Eiji ; Azuma, Koichi ; Hasegawa, Kazuo ; Yamamoto, Nobuyuki ; Nakagawa, Kazuhiko ; AstraZeneca |
Link: | |
Zeitschrift: | Lung Cancer ; volume 177, page 44-50 ; ISSN 0169-5002, 2023 |
Veröffentlichung: | Elsevier BV, 2023 |
Medientyp: | academicJournal |
DOI: | 10.1016/j.lungcan.2023.01.011 |
Schlagwort: |
|
Sonstiges: |
|